TAVO101 / Tavotek - LARVOL DELTA

A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases. (PubMed, Front Immunol) - "In addition, TAVO101 showed strong efficacy in both TSLP/OVA-induced asthma and imiquimod induced psoriasis models in hTSLP/hTSLPR double knock-in mice. We further conducted Fc engineering to optimize TAVO101 antibody with reduced affinity to Fcγ receptors and C1q protein but with increased affinity to FcRn receptor for half-life extension. By recognizing a different epitope, similarly potent neutralization of TSLP activities, and longer circulating half-life than tezepelumab, novel anti-TSLP antibody TAVO101 offers a potential best-in class therapeutics for various TSLP-mediated diseases."

Journal • Allergy • Asthma • Dermatology • Immunology • Inflammation • Oncology • Psoriasis • Pulmonary Disease • Respiratory Diseases • CD1C • CD4 • STAT5 • STAT5AWqe • TSLP

A Study of TAVO101 in Atopic Dermatitis Patients (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Tavotek Biotherapeutics | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Jun 2025

Enrollment closed • Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Study of TAVO101 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Tavotek Biotherapeutics | Active, not recruiting ➔ Completed | Trial completion date: May 2024 ➔ Sep 2024 | Trial primary completion date: Nov 2023 ➔ Jun 2024

Trial completion • Trial completion date • Trial primary completion date

A Study of TAVO101 in Atopic Dermatitis Patients (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Tavotek Biotherapeutics | Trial completion date: Jan 2025 ➔ Sep 2025 | Trial primary completion date: Oct 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions. (PubMed, J Clin Pharmacol) - "This long-acting anti-TSLP antibody has the potential for stronger and sustained allergic inflammatory disease control. The results from this study warranted further clinical development of TAVO101 in patients."

Journal • P1 data • PK/PD data • Stroma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • TSLP

A Study of TAVO101 in Atopic Dermatitis Patients (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Tavotek Biotherapeutics | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2024 ➔ Jan 2025 | Trial primary completion date: Jun 2024 ➔ Oct 2024

Enrollment open • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Engineering the anti-TSLP mAb, TAVO101, to Control Autoimmune Diseases (FOB-USA 2024) - "TAVO101 was engineered to address the challenges for the treatment of chronic autoimmune diseases. We highlight preclinical and clinical profiles of this anti-TSLP mAb."

Immunology

Study of TAVO101 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Tavotek Biotherapeutics | Trial completion date: Jan 2024 ➔ May 2024

Trial completion date

A Study of TAVO101 in Atopic Dermatitis Patients (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Tavotek Biotherapeutics

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Study of TAVO101 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Tavotek Biotherapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed

Study of TAVO101 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Tavotek Biotherapeutics | Trial completion date: May 2023 ➔ Mar 2024 | Trial primary completion date: Nov 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date

Study of TAVO101 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Tavotek Biotherapeutics | Not yet recruiting ➔ Recruiting

Enrollment open

Study of TAVO101 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Tavotek Biotherapeutics

New P1 trial